Search company, investor...

TransMolecular

transmolecular.com

Founded Year

1996

Stage

Series C | Alive

Total Raised

$42.71M

Last Raised

$33.2M | 19 yrs ago

About TransMolecular

Transmolecular is a biotechnology company targeting disorders of the central nervous system. The company is committed to discovering, developing, and commercializing targeted therapies for glioma, metastatic brain tumors, and aggressive cancers with limited treatment options.

Headquarters Location

840 Memorial Drive Second Floor

Cambridge, Massachusetts, 02139,

United States

617-995-3050

Missing: TransMolecular's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: TransMolecular's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing TransMolecular

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TransMolecular is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

TransMolecular Patents

TransMolecular has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/17/2003

3/16/2010

Transcription factors, Oncology, Rare cancers, Clusters of differentiation, Brain tumor

Grant

Application Date

10/17/2003

Grant Date

3/16/2010

Title

Related Topics

Transcription factors, Oncology, Rare cancers, Clusters of differentiation, Brain tumor

Status

Grant

TransMolecular Frequently Asked Questions (FAQ)

  • When was TransMolecular founded?

    TransMolecular was founded in 1996.

  • Where is TransMolecular's headquarters?

    TransMolecular's headquarters is located at 840 Memorial Drive, Cambridge.

  • What is TransMolecular's latest funding round?

    TransMolecular's latest funding round is Series C.

  • How much did TransMolecular raise?

    TransMolecular raised a total of $42.71M.

  • Who are the investors of TransMolecular?

    Investors of TransMolecular include TVM Capital, Pacific Horizon Ventures, President Life Science, Tullis Health Investors, Global Biomedical Partners and 12 more.

  • Who are TransMolecular's competitors?

    Competitors of TransMolecular include Aerie, Orexigen Therapeutics, ARIAD Pharmaceuticals, Dendreon, FORUM Pharmaceuticals and 13 more.

Compare TransMolecular to Competitors

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

G
Galenea

Galenea is a biopharmaceutical company discovering and developing drugs to treat schizophrenia and other central nervous system diseases. The company has developed technology, the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, which enables direct high throughput screening of synaptic function in cultured primary neurons from mice and rats, and in neurons derived from human induced pluripotent stem cells. The company is using the MANTRA system to characterize synaptic dysfunctions in disease models and to identify signatures of therapeutic compound classes.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

M
Mutabilis

Mutabilis is a French biopharmaceutical company developing novel antibacterials against Gram-negative infections. Mutabilis has expertise in diazabicyclooctane chemistry and its applications in the discovery of antibacterials and beta-lactamase inhibitors.

W
Woomera Therapeutics

Woomera was started in June of 2003 to bring science developed at Dartmouth Medical School from the lab to the clinic in the form of treatments and diagnostic tools for various cancers. Woomera is a biopharmaceutical company developing immuno-products targeting markers for the treatment of specific cancers. The Woomera technology platform aims to build upon 30 years of research by Dr. William G. North, Professor of Physiology at Dartmouth Medical School. The company opened offices in Lebanon, NH in November of 2004. In February of 2005, the company added Dr. Lyn Oligino, Ph.D. to the staff.

B
BrainCells

BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.